Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Comment by Righttothetopon Mar 04, 2021 10:20am
80 Views
Post# 32714238

RE:RE:RE:RE:CDL

RE:RE:RE:RE:CDLAs stated, anything formal drug related has absolutely zero to do with near to medium to success.  Most of us know that the drug approval odyssey is literally years and years to get even remotely close to the finish line.  And even then, how many Ph3 drugs fail even with decent efficacy data?  Tons.

Being a cannabis pharma company is a great idea, but won't matter a lick during this time when it matters most; which is now. 

It is positive that the insiders were carved off a whole lot of the recent financing if they chose....would be nice if they took a sizable bite which would then also explain why they priced the financing so low.....why not got for an easy double??

Lemoyne wrote: Canadian drug licence? They said in prospectus they do not expect de drive revenues from this licence for the foreseeable future.


<< Previous
Bullboard Posts
Next >>